Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792372 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL178744 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29374829 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL30649315 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29352017 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29768913 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29792120 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL117964 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| Water SCHEMBL22070159 | 0.99 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| Water SCHEMBL31472478 | 0.99 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024129600-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| EP-4317146-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| US-20230405157-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2023-12-21 | — | — | US | disclosed |
| WO-2023219952-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-116917280-A | Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-8168756-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-8063085-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2010-07-08 | — | — | US | disclosed |
| WO-2010048423-A1 | LEVETIRACETAM IMMUNOASSAYS | ARK DIAGNOSTICS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20090239755-A1 | Identification of Compounds Modifying A Cellular Response | 2CUREX (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090170920-A1 | SUBSTITUTED HYDANTOINS | CHEN SHAOQING | 2009-07-02 | — | — | US | disclosed |
| US-20080194537-A1 | Compounds Modifying Apoptosis | 2CUREX (DK) | 2008-08-14 | — | — | US | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405157-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | MC3R, MC1R, MC4R | MDM2 2614/4885TLR2 428/4885MDM4 3183/4885 |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | GNRHR, GHRHR, FSHR | MDM2 3999/4885TLR2 3825/4885MDM4 4807/4885 |
| US-20080194537-A1 | Compounds Modifying Apoptosis | API5, BAX, BAD | MDM2 165/4885TLR2 4725/4885MDM4 486/4885 |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | MDM2 4789/4885TLR2 2440/4885MDM4 4496/4885 |
| US-20090239755-A1 | Identification of Compounds Modifying A Cellular Response | MCL1, PMAIP1, CDC37 | MDM2 360/4885TLR2 3969/4885MDM4 169/4885 |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | MDM2 4089/4885TLR2 1069/4885MDM4 4385/4885 |
| US-20090170920-A1 | SUBSTITUTED HYDANTOINS | HNMT, HRH3, BRAF | MDM2 3189/4885TLR2 913/4885MDM4 3885/4885 |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | GABRG1, GABRA6, LY96 | MDM2 3125/4885TLR2 4281/4885MDM4 4695/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | MDM2 1920/4885TLR2 4454/4885MDM4 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.